Unknown

Dataset Information

0

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

ABSTRACT: OBJECTIVE:VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients. METHODS:In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (?8?weeks) who needed to change regimen for virologic failure (viral load???500?copies/mL) or simplification/adverse events (viral load?

SUBMITTER: Arathoon E 

PROVIDER: S-EPMC5367767 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

Arathoon Eduardo E   Bhorat Asad A   Silaghi Rodica R   Crauwels Herta H   Lavreys Ludo L   Tambuyzer Lotke L   Van Baelen Ben B   Vanveggel Simon S   Opsomer Magda M  

SAGE open medicine 20170118

<h4>Objective</h4>VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients.<h4>Methods</h4>In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (⩾8 weeks) who needed to change regimen for virologic failure (viral load ⩾ 500 copies/mL) or simplification/adverse events (viral load < 50 copies/mL) received etravirine 200 mg bid w  ...[more]

Similar Datasets

Unknown Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
| S-EPMC3088221 | biostudies-literature
Unknown Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.
| S-EPMC3874356 | biostudies-literature
Unknown Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
| S-EPMC3067092 | biostudies-literature
Unknown Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
| S-EPMC4312629 | biostudies-literature
Unknown Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
| S-EPMC3448095 | biostudies-literature
Unknown Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
| S-EPMC5907875 | biostudies-literature
Unknown Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
| S-EPMC5407125 | biostudies-literature
Unknown Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
| S-EPMC5546302 | biostudies-literature
Unknown Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.
| S-EPMC3318205 | biostudies-literature
Unknown Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
| S-EPMC6336297 | biostudies-literature